SWOT Analysis for Transgene Biotek Ltd.

Relative Outperformance versus Industry over 1 Month
Rising Net Cash Flow and Cash from Operating activity
High Momentum Scores (Technical Scores greater than 50)
Relative Outperformance versus Industry over 1 Month
Effectively using its capital to generate profit - RoCE improving in last 2 years
Strong cash generating ability from core business - Improving Cash Flow from operation for last 2 years
Company able to generate Net Cash - Improving Net Cash Flow for last 2 years
Companies with Zero Promoter Pledge
Stock gained more than 20% in one month
Stock with Low PE (PE < = 10)
Stocks in uptrend most likely to cross above SMA-200 soon
Stocks Outperforming their Industry Price Change in the Quarter

PEG greater than Industry PEG
Stocks with Expensive Valuations according to the Trendlyne Valuation Score
Declining profits every quarter for the past 3 quarters
Low Piotroski Score : Companies with weak financials
Book Value Per Share deteriorating for last 2 years
Companies Increasing Debt as per Annual Report
Highest fall from 52 Week High

Average Bullish Trend - Stocks with Medium Trendlyne Momentum Score versus Benchmarks
Decline in Net Profit with falling Profit Margin (QoQ)

Transgene Biotek Ltd. SWOT Analysis: Strengths, Weakness, Opportunity, and Threats